Patents for A61P 35 - Antineoplastic agents (221,099)
02/2008
02/28/2008US20080051347 Tumour-associated peptides binding to mhc-molecules
02/28/2008US20080051346 Compounds and methods for modulating cell-adhesion mediated drug resistance
02/28/2008US20080051345 Pharmaceutical compositions comprising fragments and homologs of troponin subunits
02/28/2008US20080051339 Modulators of pharmacological agents
02/28/2008US20080051338 98 Human Secreted Proteins
02/28/2008US20080051337 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
02/28/2008US20080051327 Crystals of an Aurora-A Tpx2 Complex, Tpx2 Binding Site of Aurora-A, Aurora-A Ligands and Their Use
02/28/2008US20080051323 Chloroquine drug compositions and methods for their synthesis
02/28/2008US20080050797 Transferase for use in identifying modulators for prevention and treatment of cell proliferative disorders
02/28/2008US20080050719 Gene expression profiles in liver disease
02/28/2008US20080050448 Antimicrobial conjugates
02/28/2008US20080050425 Combination Chemotherapy Comprising 5-Fluorouracil or a Derivative Thereof and a Liposomal Platinum Complex
02/28/2008US20080050390 Administration of gamma globulins to treat metastatic melanoma
02/28/2008US20080050388 Specified complementary determining region (CRD) amino acid sequences; specific binding activity for a cryptic collagen epitope; angiogenesis inhibition, antimetastasis, and tumor-targeted therapy uses
02/28/2008US20080050385 Tumor therapy with an anti-vegf antibody
02/28/2008US20080050384 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
02/28/2008US20080050377 consensus sequences and specific sequences for antibodies that specifically bind to STOP-1; angiogenesis and vasculogenesis; antitumor agents
02/28/2008US20080050373 Treatment with anti-erbb2 antibodies
02/28/2008US20080050368 Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
02/28/2008US20080050362 Methods of Inhibiting Tumor Cell Aggressiveness Using The Microenvironment of Human Embryonic Stem Cells
02/28/2008US20080050341 Adoptive Immunotherapy with Enhanced T Lymphocyte Survival
02/28/2008US20080050317 Oleaginous pharmaceutical and cosmetic foam
02/28/2008DE19955576B4 Transferverbindungen, ihre Herstellung und ihre Verwendung Transfer compounds, their preparation and their use
02/28/2008CA2838089A1 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
02/28/2008CA2661546A1 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
02/28/2008CA2661436A1 Isoquinoline, quinazoline and phthalazine derivatives
02/28/2008CA2661422A1 Methods and compositions for treating cancer
02/28/2008CA2661333A1 Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
02/28/2008CA2661166A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
02/28/2008CA2661054A1 Prophylactic and/or therapeutic agents for peripheral neuropathy
02/28/2008CA2660963A1 Aza-benzothiophenyl compounds and methods of use
02/28/2008CA2660957A1 2-phenoxy pyrimidinone analogues
02/28/2008CA2660546A1 Aza-benzofuranyl compounds and methods of use
02/28/2008CA2660531A1 Compounds for treatment of proliferative disorders
02/28/2008CA2660524A1 Compounds for treating proliferative disorders
02/28/2008CA2660169A1 Fluorinated ligands for targeting peripheral benzodiazepine receptors
02/28/2008CA2648521A1 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-n0r-vitamin d compounds with a 1,1-dimethylpropyl side chain
02/27/2008EP1892301A1 Method for evaluation of compound using rsk1
02/27/2008EP1892299A2 Sense mRNA therapy
02/27/2008EP1892251A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
02/27/2008EP1892250A2 CYR61 compositions and methods
02/27/2008EP1891957A1 Purified Compositions of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same in the Treament of Tumors
02/27/2008EP1891228A2 Hdac regulation assays, compounds and therapeutic compositions
02/27/2008EP1891115A2 Anti her2/neu antibody
02/27/2008EP1891114A2 Anti-trkb monoclonal antibodies and uses thereof
02/27/2008EP1891113A2 Antibodies directed to cd20 and uses thereof
02/27/2008EP1891102A2 Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
02/27/2008EP1891082A1 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer
02/27/2008EP1891076A1 Substituted tetrahydroquinolines
02/27/2008EP1891066A2 Compounds and compositions as protein kinase inhibitors
02/27/2008EP1891052A1 Tubulin inhibitor and process for its preparation
02/27/2008EP1891048A1 Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
02/27/2008EP1891047A2 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
02/27/2008EP1891017A1 Nitrogen heterocycle biaryls for osteoporosis and other diseases
02/27/2008EP1891013A1 Tetrahydroquinoline derivatives
02/27/2008EP1891011A1 Tetrahydroquinolines used in the form of modulators of mitotic motor-proteins eg5
02/27/2008EP1891008A1 Oxindoles as kinase inhibitors
02/27/2008EP1891007A1 Indole derivatives having antitumor activity
02/27/2008EP1890724A2 Compositions for inducing an immune response
02/27/2008EP1890723A2 Stabilised il-21 compositions
02/27/2008EP1890683A1 Methods of supressing uv light-induced skin carcinogenesis
02/27/2008EP1890546A1 A composition to enhance the bioavailability of curcumin
02/27/2008EP1890537A1 Methods of treating cancer and other conditions or disease states using lfmau and ldt
02/27/2008EP1716155B1 Substituted thieno- and thiazolo[2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2
02/27/2008EP1697356B1 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
02/27/2008EP1581531B1 Pyridino¬2,3-d pyrimidine derivatives as selectiive kdr and fgfr inhibitors
02/27/2008EP1562955B1 Quinazoline derivatives as src tyrosine kinase inhibitors
02/27/2008EP1558616B1 Meso-substituted porphyrins
02/27/2008EP1509251B1 Nucleic acids, polypeptides, and methods for modulating apoptosis
02/27/2008EP1506192B1 Substituted pyrroline kinase inhibitors
02/27/2008EP1485719B1 Peptide epitopes common to antigens of the same multigene family
02/27/2008EP1453827B1 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof
02/27/2008EP1446115B1 Cyanoalkylamino derivatives as protease inhibitors
02/27/2008EP1438393B1 Differentiation of whole bone marrow
02/27/2008EP1341811B1 Orally ingestible preparation of mistletoe lectins and method
02/27/2008EP1329504B1 Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
02/27/2008EP1282700B1 Neuronal serine-threonine protein kinase
02/27/2008EP1248612B1 Novel compounds and compositions as protease inhibitors
02/27/2008EP1150959B1 Solid-state form of celecoxib having enhanced bioavailability
02/27/2008EP1149105B1 4,5-pyrazinoxindoles as protein kinase inhibitors
02/27/2008EP1141278B1 Therapeutic pde4d phosphodiesterase inhibitors
02/27/2008CN101133083A 人源化的抗cd47抗体 Humanized anti-cd47 antibody
02/27/2008CN101133065A Purification of rapamycin
02/27/2008CN101133061A Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-ce]indol-6-one
02/27/2008CN101133060A Enzyme inhibitors
02/27/2008CN101133055A Compositions and methods for treatment of cancer
02/27/2008CN101133051A Quinoxaline dihydrohalide dihydrates and synthetic methods thereof
02/27/2008CN101133024A Amide derivatives as inhibitors of histone deacetylase
02/27/2008CN101133023A Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof
02/27/2008CN101132813A BLYS fusion proteins for targeting BLYS receptor and methods for treatment of B-cell proliferative disorders
02/27/2008CN101132809A Methods for treating renal cell carcinoma
02/27/2008CN101132798A Method and composition for treatment of neoplasms
02/27/2008CN101132779A Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
02/27/2008CN101130779A Method for regulating and controlling adenovirus protein by double promoter and use thereof
02/27/2008CN101130724A Health care beer having auxiliary inhibit function for tumour and method of producing the same
02/27/2008CN101130571A Human ring protein, encoding gene and application of the same
02/27/2008CN101130567A Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
02/27/2008CN101130566A Method of preparing 23,24-dihydrocucurbitacin B and use of the same in medicament for treating tumour
02/27/2008CN101130556A Anticancer diaminocyclohexane metallic complex
02/27/2008CN101130539A Indole-substituteing imidazoline-2-ketones derivant, preparing method and uses of the same